Open AccessClinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use
Author(s) -
Esteban SáezGonzález,
Francia Carolina Díaz Jaime,
A. del Val Antoñana
Publication year - 2016
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2016.4340/2016
Subject(s) - medicine , olmesartan , enteropathy , sprue , villous atrophy , hypoalbuminemia , gastroenterology , diarrhea , serology , biopsy , pathology , coeliac disease , immunology , blood pressure , disease , antibody , mold , biology , genetics
Olmesartan is one of the various angiotensin II antagonists currently used for the management of high blood pressure. A sprue-like enteropathy was first described in 2012 in association with this antihypertensive drug. An observational, descriptive study was carried out on a series of 12 patients who met the clinical, histopathological, and outcome criteria for olmesartan-related sprue-like enteropathy from May 2013 to December 2015. All patients had watery diarrhea, weight loss, and negative celiac serology. They all were admitted with severe illness including dehydration with prerenal kidney failure, metabolic acidosis, water-electrolyte imbalance, and malnutrition parameters. Most common laboratory abnormalities included anemia and hypoalbuminemia. Duodenal biopsy histology revealed villous atrophy in all 12 patients. They all responded well to drug discontinuation, and 100% of individuals with follow-up biopsy showed histological recovery. Olmesartan should therefore be considered a potential cause of severe diarrhea, particularly in patients with duodenal villous atrophy and negative celiac serology.